A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Active:	Yes
Cancer Type:	Breast Cancer	NCT ID:	NCT05514054
Trial Phases:	Phase III	Protocol IDs:	18459 (primary) NCI-2022-08126 2022-501007-28 J2J-MC-JZLH
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Eli Lilly and Company
NCI Full Details:	http://clinicaltrials.gov/show/NCT05514054

Summary

The main purpose of this study is to measure how well imlunestrant works compared to
standard hormone therapy in participants with early breast cancer that is estrogen
receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants
must have already taken endocrine therapy for two to five years and must have a
higher-than-average risk for their cancer to return. Study participation could last up to
10 years.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
404-778-5180
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.